Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190021/S012

ReActiv8 Implantable Neurostimulation System

Mainstay Medical Limited · Decision date Oct 19, 2026

MEDTECHLEDGER EXPLANATIONP190021/S012

What did the FDA approve?

The FDA record for P190021/S012 describes a real-time process supplement to the ReActiv8 implantable neurostimulation system PMA held by Mainstay Medical Limited. The stated purpose is approval of revised magnetic resonance compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual, now covering lead fragments up to 2 cm in length. The supplement carries a labeling-change reason tied to indications, instructions, shelf life, or tradename, and sits in the neuromuscular lower-back stimulator category for pain relief.

The identifier shows P190021 is the original PMA, so S012 is a supplement, not a new approval of the whole system. The record does not explain the prior lead-fragment limit, how the 2 cm figure was derived, or what testing supports it; the approval reflects the agency's labeling decision, not an independent finding of safety or clinical effectiveness reported here. Details on MRI field conditions and the full manual text remain absent from the supplied fields.

FDA approval order statement

approval for revised magnetic resonance (MR) compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual to include lead fragments up to 2 cm in length.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Oct 19, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P190021/S012
Regulatory pathway
PMA supplement
Product code
QLK
Decision code
APPR
Decision date
Oct 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief.

Product code
QLK
FDA device class
3

For the original device and its historical approval scope, see PMA P190021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190021 · Original PMA

    ReActiv8 Implantable Neurostimulation System

  2. P190021/S012 received

    Application receipt date recorded by FDA.

  3. P190021/S012 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P190021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190021

Product / regulatory recordCompanyPathwayDecision dateSource
Mainstay Medical LimitedPMA approvalJun 16, 2020FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Mainstay Medical Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Clonmel House Forster Way, Swords, Co Dublin, K67F2K3

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records